Featured
Last news
Wi2Wi Corporation Announces Third Quarter 2025 Financial Results and Leadership Transition
TORONTO, ON / ACCESS Newswire / November 18, 2025 / Wi2Wi Corporation (TSX-V:YTY)(OTC:ISEYF) a leader in precision timing devices, frequency control products, and wireless technologies, today announced its financial results for the third quarter ended September 30, 2025 and leadership transition.
Brenmiller to Present at Enlit Europe 2025: Leading High-Impact Sessions on Energy Storage and AI Shaping the Future of Clean Energy
Brenmiller's Spain-based joint venture currently has projects in development and collaborations across the European Union
MDaudit's 2025 Benchmark Report Reveals Ongoing Acceleration of Payer Audits, Troubling Rise in Denials and Outpatient Coding Issues
Annual analysis points to an urgent need to redefine revenue integrity as proactive protection, while strengthening coding integrity and denial prevention measures.
Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome
Meeting with Radiological and Nuclear Medical Countermeasures Program
Food Culture Inc. (OTCID:FCUL) Completes Acquisition of Distill Brands International and Appoints Mr. Paul Neelin as Incoming CEO
Food Culture completes transition from distribution of ready-to-eat meals to the global spirits marketing industry
A Conversation With DDC CEO Norma Chu: Building a Company That Honors Its Roots While Preparing for the Next Decade
NEW YORK, NY / ACCESS Newswire / November 18, 2025 / For most consumers, DDC still feels familiar, the brands, the flavors, the recipes that built its early following. But underneath that cultural foundation, something larger has been taking shape. Over the last several months, DDC Enterprise Limited (NYSE American:DDC) has strengthened its food platform, expanded distribution across key markets, and quietly assembled one of the most closely watched corporate treasuries in the consumer sector.
RMTG Subsidiary CELLGENIC Introduces Peptide Pen Product Line at Cancún Global Summit
Pre-Loaded Synergistic Peptide Formulations Add New Revenue Stream Through Physician Distribution Network Spanning 30+ Countries
Avel eCare Specialty Clinic Surpasses 100,000 Patient Encounters, Expanding Access to Specialty Care Across Rural America
SIOUX FALLS, SD / ACCESS Newswire / November 18, 2025 / Avel eCare announced a landmark achievement this week as its Specialty Clinic service line officially surpassed 100,000 patient encounters - marking a major milestone in the company's mission to deliver equitable specialty care to rural, remote, and underserved communities across the United States.
CBMJ: Patriot.TV Surpasses 2 Million Monthly Rumble Views for First Time-Outpacing Legacy Media and Accelerating Growth Ahead of 2026
Patriot.TV (CBMJ) growth exceeds Disney (DIS), Paramount Global (PARA), Comcast (CMCSA), Newsmax (NMAX), Sinclair (SBGI), Warner Bros. Discovery (WBD), and even Fox Corp. (FOX)
Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference
LAVAL, QC / ACCESS Newswire / November 18, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.
CBD Life Sciences Inc. (CBDL) Secures Exclusive Launch of New Anti-Inflammatory "Soothe Gel" Across Two Red Hots Spa Locations in New York
With the global pain-management market projected to surpass $93.9 billion by 2030 and topical analgesics growing at a 7.2% CAGR, CBDL positions itself for major East Coast expansion amid surging consumer demand for natural relief solutions.
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:
Delhi car bombing accused appears in Indian court, another suspect held
Indian anti-terrorism investigators presented a suspect linked to last week's deadly car bomb in New Delhi in court on Monday, one of three men now accused of involvement in the suicide attack.
Death toll from Indonesia landslides rises to 18
The death toll from three landslides that hit Indonesia's Java island since last week has risen to 18, with more than 30 people missing, a disaster official said on Monday.
Bangladesh ex-PM sentenced to death for crimes against humanity
A Bangladesh court on Monday sentenced ousted prime minister Sheikh Hasina to death for crimes against humanity, with cheers breaking out in the packed court as the judge read out the verdict.
Singapore jails 'attention seeking' Australian over Ariana Grande incident
A Singapore court sentenced an Australian man to nine days in jail on Monday for rushing film star Ariana Grande at the Asian premiere of "Wicked: For Good" last week.
Bangladesh verdict due in ex-PM's crimes against humanity trial
Bangladeshi judges will deliver their verdict on Monday in the crimes against humanity trial of fugitive former prime minister Sheikh Hasina, a highly anticipated ruling before the first polls since her overthrow.
TrizCom Public Relations Wins Its Third PRSA Best of Show Award
Agency honored for Peppa Pig Theme Park Dallas/Fort Worth grand opening campaign at PRSA Dallas Pegasus Awards
Envela to Present at the 17th Annual Southwest IDEAS Investor Conference
IRVING, TX / ACCESS Newswire / November 17, 2025 / Envela Corporation ("Envela" or the "Company") today announced that it will present at the Southwest IDEAS Investor Conference on Thursday, November 20, 2025, at The Westin Las Colinas in Dallas, TX.
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
ORLANDO, FLORIDA / ACCESS Newswire / November 17, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced it has completed the initial stage of a strategic realignment by acquiring a controlling interest in LAMY, an SEC-reporting company (OTCID:LMMY), in exchange for Exousia Pro's subsidiary, Exousia AI, Inc., in an all-stock transaction. Exousia Pro received approximately 51% of LMMY restricted Common Stock, positioning MAJI as the controlling shareholder of LMMY.
D.C. Circuit Grills DEA Over Years Long Delays as MMJ BioPharma Cultivation Demands Timely Ruling on Cannabis Grow
From Iowaska Church to MMJ BioPharma Cultivation, Appellate Courts Patience with DEA's Inaction Wears Thin Amid Constitutional Challenges.Administrator Terrance "Terry" Cole must issue a final order "as soon as practicable." The Administrative Procedure Act likewise requires agencies to "proceed to conclude a matter presented to [them]" within a reasonable time.
MEDevice Silicon Valley 2025 Keynotes to Feature Visionary MedTech Leaders
SANTA CLARA, CA / ACCESS Newswire / November 17, 2025 / MEDevice Silicon Valley 2025 (November 19-20, Santa Clara Convention Center) is set to deliver keynote presentations featuring visionary MedTech leaders who will discuss the latest developments in artificial intelligence, robotics, digital health and innovation.
Avrio Announces the Appointment of James O'Neill as Chief Investment Officer to Lead Global Investment and Capital Markets Strategy
NEW YORK, NY, LONDON, UK, and ABU DHABI, UAE /ACCESS Newswire / November 17, 2025 / Avrio Worldwide PBC ("Avrio"), a global financial services technology company providing institutional-grade market infrastructure, services, and data across public, private, and digital markets, today announced the appointment of James O'Neill as Chief Investment Officer (CIO).
Compassion Center, the Las Vegas Community, and Loved Ones Honor the Life and Immeasurable Legacy of Julie "Nurse Juhlzie" Monteiro with Community Celebrations December 13-14, 2025
It is with the greatest of sadness and the deepest of regret that Compassion Center announces the passing of its most beloved, precious, fearless, and courageous leader, Julie "Nurse Juhlzie" Monteiro (Creel), who peacefully transitioned of natural causes on November 11th, 2025, in the comfort, warmth, and sanctuary of her cozy king-sized bed.
VSEE Health, Inc. Delivers Robust Q3 2025 Revenue Growth Amid Telehealth Expansion: Total Revenues Reach $3.98 Million, Up 19% Year-Over-Year
SAN JOSE, CALIFORNIA / ACCESS Newswire / November 17, 2025 / VSee Health, Inc. (Nasdaq:VSEE), a pioneering provider of AI-powered telehealth solutions and high-acuity virtual care services, today announced its financial results for the third quarter ended September 30, 2025, as detailed in its Form 10-Q filed with the SEC on November 14, 2025.
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the blood-brain barrier, potentially enhancing efficacy for patientsLead program, TPI 287, progressing toward Phase 2 study for treatment of glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer, with a median survival of only around 15 months from the time of diagnosis
Kultura Brands (OTC:LTNC) Announces Official Launch Elevate Health & Wellness Gummies
KULTURA BRANDS (OTCID: LTNC) ANNOUNCES OFFICIAL LAUNCH ELEVATE HEALTH & WELLNESS GUMMIES NOW AVAILABLE FOR B2B THROUGH CENCORA MARKETPLACE AND DIRECT-TO-CONSUMER AT LOCKDIN.COM; THIRST RESPONDER HYDRATION LAUNCHES MID-DECEMBER; PORTION OF ALL SALES BENEFITS THE MANNY PACQUIAO FOUNDATION
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange Commission (SEC) on Friday, November 14, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000110465925112608/nnvc-20250930x10q.htm).
Modular Medical Receives IRB Approval to Deliver Insulin Using Pivot Patch Pump
Study to Deliver Insulin to Internal Testers Wearing Continuous Glucose Monitors
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVIDCompany completed meeting with FDA October 2, 2025 for advice on possible expedited approval pathway to advance its ongoing placebo-controlled trial of crofelemer for potential approval for treatment of MVIDREMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q3 2025 financials and company updates; Click here to register
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment.